AiViva Biopharma

JEL delivery technology

AIV007-E02 Clin1/Clin2 wet AMD, DME: undisclosed Clin0 BPH, prostate cancer; undisclosed Clin0 solid tumors

AiViva Biopharma is developing innovative drug delivery systems to address unmet medical needs. Their core technology, JEL, prolongs the therapeutic effects of drugs and enhances their safety profile. AiViva is exploring applications of this technology across various therapeutic areas, including oncology and urology. In oncology, they are developing drug candidates to directly target solid tumors, potentially leading to improved treatment outcomes. Their urology pipeline includes a product for benign prostatic hyperplasia (BPH) designed to offer a less invasive and more effective treatment option compared to existing therapies.